Remus Pharmaceuticals (NSE:REMUS) FFO


NSE:REMUS Remus Pharmaceuticals Ltd NSE:REMUS
55 GF Score
Price ₹793.70
GF Value ₹2,071.36
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Remus Pharmaceuticals FFO?

FFO (Funds from operations) only applies to REITs.

NSE:REMUS
55GF Score
Remus Pharmaceuticals Ltd NSE:REMUS
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Remus Pharmaceuticals (NSE:REMUS) Overvalued in 2026?

Based on GuruFocus' analysis, Remus Pharmaceuticals stock appears to be undervalued. The current stock price of ₹793.70 is trading 61.7% below its estimated GF Value™ of ₹2,071.36. GuruFocus considers Remus Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for NSE:REMUS:

  • FFO:
  • GF Value™: ₹2,071.36 vs. price of ₹793.70 (61.7% below fair value)
  • GF Score™: 55/100 with 2 warning signs

No single metric tells the full story. See the NSE:REMUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Remus Pharmaceuticals Business Description

Address Ambli bopal Road, 1101 to 1103, South Tower, One 42, Behind Ashok Vatika, Near Jayantilal Park BRTS, Ahmedabad, GJ, IND, 380054
Remus Pharmaceuticals Ltd is engaged in the marketing & distribution of finished formulations of pharmaceutical drugs. The company also deals in API (Active Pharmaceutical Ingredient). It also provides technical consultancy services to various distributors for the preparation of reports on the dossiers of the products to be registered by them in various countries. Remus Pharmaceuticals market niche medicinal combinations. It exports generic drugs by conducting intensive market research in the pharmaceutical industry to expand its product portfolio.
55GF Score

Get the complete analysis for NSE:REMUS

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹793.70
Price
₹2,071.36
GF Value